心血管外科医生竞争风险分析实用指南
本文为胸心血管外科医生提供与生物统计学家合作实施竞争风险分析的实用分步策略。通过模拟的心血管外科示例(Norwood一期成功后,二期双向Glenn期间死亡作为竞争风险,分析早产与三期Fontan术后死亡风险),展示竞争风险分析可改变传统生存分析结论。
要点
- 传统生存分析错误假设非信息性删失,竞争风险存在时结果无效。
- 竞争风险分析步骤:判断需求、非参数分析、模型分析、解释结果、与传统方法比较。
- 示例中Cox回归显示早产显著(HR 1.26),Fine-Gray模型则无统计学意义(HR 1.07)。
核心结论
- 竞争风险分析在存在竞争事件时优于传统生存分析,可避免无效结论。
研究设计与样本
- 方法学文章,提出分步策略,并应用于假设的心血管外科示例:Norwood一期成功后,二期双向Glenn期间死亡作为竞争风险,分析早产与三期Fontan术后死亡风险。
主要发现
- Cox回归显示早产是三期术后死亡的显著危险因素(HR 1.26;95%CI 1.06-1.50;P=.009)。
- Fine-Gray竞争风险模型显示早产不是显著预测因素(HR 1.07;95%CI 0.90-1.27;P=.467)。
临床怎么用
- 心血管外科医生分析时间-事件数据时,应与生物统计学家合作,按步骤判断并实施竞争风险分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The purpose of this article is to provide thoracic and cardiovascular surgeons with a practical step-by-step strategy to use in collaboration with a biostatistician for implementation of competing risks analysis when analyzing time-to-event data. Patients may have an outside event that precludes the event of interest. Traditional time-to-event analysis incorrectly assumes noninformative censoring in this scenario, which will lead to invalid results and conclusions. METHODS: The steps are (1) to determine whether competing risks analysis is needed, (2) to perform a nonparametric analysis, (3) to perform a model-based analysis, (4) to interpret the results, and (5) to compare to traditional survival analysis methods. We apply our approach to a hypothetical cardiovascular surgery example in determining the hazard of mortality after the stage 3 Fontan operation associated with prematurity among patients with hypoplastic left heart syndrome who had successful completion of Norwood stage 1 while incorporating mortality during the stage 2 bidirectional Glenn procedure as a competing risk. We apply nonparametric, semiparametric, and parametric methods. RESULTS: Although Cox regression establishes prematurity as a significant risk factor of mortality after stage 3 (hazard ratio, 1.26; 95% confidence interval, 1.06-1.50; P = .009), the competing risks analysis with the Fine-Gray model accounting for mortality after stage 2 determines that prematurity is not a significant predictor (hazard ratio, 1.07; 95% confidence interval, 0.90-1.27; P = .467). CONCLUSIONS: This article provides a practical step-by-step approach for making competing risks more accessible for cardiac surgeons collaborating with a biostatistician in analyzing and interpreting time-to-event data.
引用
- Staffa SJ, Zurakowski D. Competing risks analysis of time-to-event data for cardiovascular surgeons. J Thorac Cardiovasc Surg. 2019. PMID: 31866080. doi:10.1016/j.jtcvs.2019.10.153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。